GEn1E is a clinical-stage multi-target AI platform. They develop novel, next-gen, immunomodulators for rare & inflammatory diseases.
Gen1E Lifesciences has raised $5.5M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2025.
Gen1E Lifesciences's investors include Khosla Ventures, Y Combinator, Bossa Invest, Leblon Capital, Milad Alucozai.
Gen1E Lifesciences is headquartered in Palo Alto, United States.
GEn1E is a clinical-stage multi-target AI platform. They develop novel, next-gen, immunomodulators for rare & inflammatory diseases.
Gen1E Lifesciences is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Gen1E Lifesciences — Funding & Investors." VCBacked, December 23, 2025, https://www.vcbacked.co/company/gen1e-lifesciences. Accessed August 15, 2026.
VCBacked. (2025). Gen1E Lifesciences — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/gen1e-lifesciences
{{cite web |title=Gen1E Lifesciences — Funding & Investors |url=https://www.vcbacked.co/company/gen1e-lifesciences |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated